El ribósido de nicotinamida (NR) y el mononucleótido de nicotinamida (NMN) orales hacen una cosa de forma fiable: tomados por vía oral, elevan el NAD+ en sangre, de forma dependiente de la dosis, en varios ensayos aleatorizados. Que ese marcador elevado cambie cómo se siente, rinde o envejece una persona es algo por resolver. Los ensayos en humanos sobre la fuerza muscular, el control de la glucosa y los marcadores del envejecimiento arrojan en su mayoría resultados pequeños, dispares o nulos, incluso allí donde los mismos compuestos logran cosas llamativas en ratones envejecidos.
Así que elevar el NAD+ está demostrado; que reponerlo prolongue el periodo de vida sana o la longevidad en humanos, no. Esta página coloca cada afirmación donde la sitúa la evidencia, cubre la situación del NMN ante la FDA y el historial de seguridad a corto plazo, y explica en qué se diferencia una cápsula diaria de un goteo intravenoso de NAD+.
Findings & Outcomes
What It Is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses to turn food into usable energy and to run its repair and signaling enzymes. Its level drifts down with age across many tissues, and that decline is the rationale behind the whole precursor category. NMN and NR are two precursor molecules the body converts into NAD+, sold as capsules or powder to top the pool back up. Both are relatives of vitamin B3, and NR and NMN raise NAD+ more than an ordinary diet does.
How It Works
Built from vitamin B3, NAD+ powers the enzymes of energy metabolism and feeds repair systems such as the sirtuins and the PARPs. Two of those steps are settled: NAD+ falls with age, and the precursors raise it back up.
Anatomy of the Practice
1The rationale: NAD+ falls with age
NAD+ is central to energy metabolism and cellular repair, and its levels decline with age in many tissues. That decline is why the precursor category exists: the hope is that restoring NAD+ toward a younger level restores some of what falls with it. The decline itself is well described.
2What the precursors do in the blood
Taken by mouth, NR and NMN are absorbed and converted into NAD+, and human trials consistently measure a rise in blood NAD+ and its metabolites within weeks. This is the dependable, replicated part. The marker rises, and it rises in a dose-related way, a pharmacological effect that is not in dispute.
3From a marker to an outcome
In the human trials blood NAD+ rose while strength, insulin sensitivity, and aging markers stayed where they were. A higher number on a lab report is one thing. Whether the extra NAD+ reaches the tissues that matter and does useful work there is what the functional trials must settle, and so far they mostly have not.
An intravenous NAD+ drip delivers NAD+ by a different route but runs into the same limit, and it rests on even less controlled outcome evidence than the oral capsules. For where NAD+ decline sits among the drivers of aging, see the biology of aging; for the cell structures it helps power, see the mitochondria.
What It Does
People buy a daily capsule on a simple chain: the level drops with age, precursors lift it, so lifting it should slow aging. That chain rests on animal work, and the animal work is the strong part. In aged mice, restoring NAD+ improves metabolism, muscle, and healthspan, and the field holds some of the more reproducible results in aging biology.
The human evidence sorts into tiers, strongest first. Firmest is the raised NAD+ level itself. The weak point is the payoff people pay for: added up, the precursors have not moved glucose, lipids, or muscle strength in ordinary adults over 60. Between that firm marker and those null results sit two preliminary leads in narrow groups. Above everything sits the headline claim with no completed human trial behind it, that a precursor extends healthspan or lifespan.
The weak point is the payoff people pay for: added up, the precursors have not moved glucose, lipids, or muscle strength in ordinary adults over 60.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
El NR y el NMN orales elevan de forma fiable el NAD+ en sangre, de manera dependiente de la dosis (el NMN se probó a 300-900 mg al día)
Tomar NR o NMN por vía oral eleva de forma fiable el nivel de NAD+ en sangre. Este es el único efecto sobre el que la evidencia en humanos es sólida.
En un ensayo cruzado aleatorizado, doble ciego, de 2x6 semanas (Martens et al. 2018, Nat Commun), la suplementación crónica con NR en adultos sanos de mediana edad y mayores fue bien tolerada y estimuló eficazmente el metabolismo del NAD+. La farmacocinética en el primer estudio en humanos (Trammell et al. 2016, Nat Commun) mostró que dosis únicas orales de NR elevaban el metaboloma de NAD+ en sangre de forma dependiente de la dosis. Un ensayo de rango de dosis de NMN (Yi et al. 2023, GeroScience) encontró que el NAD+ en sangre aumentaba significativamente a 300, 600 y 900 mg/día frente al placebo y al valor basal, siendo más alto en las dos dosis más altas.
Who this may not transfer to:The rise in blood NAD+ is measured in both sexes across NR and NMN trials; it is a pharmacodynamic marker, so it does not by itself transfer to any clinical benefit.
The studies · 3
Martens et al. 2018, Nat Commun (NR elevates NAD+ in middle-aged and older adults) · Nat Commun
Trammell et al. 2016, Nat Commun (NR orally bioavailable in mice and humans) · Nat Commun
Yi et al. 2023, GeroScience (dose-dependent NMN trial) · GeroScience
El NAD+ disminuye con la edad, la premisa para suplementar, aunque no se ha demostrado que restaurarlo revierta el envejecimiento
El NAD+ tiende a disminuir a medida que envejecemos, que es la razón por la que las personas toman precursores para reponerlo. La disminución está bien descrita; si revertirla ayuda es una cuestión aparte.
Las revisiones de la biología del NAD+ (Lautrup et al. 2019, Cell Metab) describen una disminución del NAD+ relacionada con la edad en todos los tejidos, con efectos posteriores sobre la actividad de las sirtuinas y la PARP, la reparación del ADN y la función mitocondrial. Esta disminución es la premisa mecanística para el uso de precursores de NAD+; la revisión plantea la restauración como una hipótesis por probar, no como una intervención antienvejecimiento establecida.
Who this may not transfer to:The age-related NAD+ decline is described across tissues in both sexes; it is a biological rationale, not a population outcome.
The study · 1
Lautrup et al. 2019, Cell Metab (NAD+ in brain aging and neurodegeneration) · Cell Metab
Blood Sugar
Al combinar 8 ensayos en 342 adultos, el NMN no modificó la glucosa, la insulina, la HbA1c ni los lípidos
Al sumar todos los ensayos de NMN, no redujo el azúcar en sangre, la insulina ni el colesterol en promedio. El beneficio metabólico general que las personas esperan no apareció.
Una revisión sistemática y metaanálisis (Chen et al. 2024, Curr Diab Rep) combinó ocho ECA con un total de 342 adultos de mediana edad y mayores, 49 % mujeres y en su mayoría no diabéticos, con dosis de NMN de 250 a 2000 mg/día durante 14 días a 12 semanas. Los metaanálisis de efectos aleatorios no encontraron un beneficio significativo sobre la glucosa en ayunas, la insulina en ayunas, la hemoglobina glucosilada, el HOMA-IR o el perfil lipídico.
Who this may not transfer to:The pooled null was in mostly non-diabetic middle-aged and older adults of both sexes, so it does not rule out an effect in metabolically impaired groups.
The study · 1
Chen et al. 2024, Curr Diab Rep (NMN on glucose and lipid metabolism meta-analysis) · Curr Diab Rep
El NMN a 250 mg al día durante 10 semanas aumentó la sensibilidad muscular a la insulina en 25 mujeres posmenopáusicas prediabéticas
En mujeres posmenopáusicas con prediabetes, diez semanas de NMN mejoraron la respuesta de su músculo a la insulina. Se trata de un único ensayo pequeño en un grupo específico.
Un ensayo aleatorizado, doble ciego y controlado con placebo de 10 semanas (Yoshino et al. 2021, Science; n=25) en mujeres posmenopáusicas con sobrepeso u obesidad y prediabetes encontró que el NMN a 250 mg/día aumentó la eliminación de glucosa estimulada por insulina medida por pinza, elevó la fosforilación de AKT y mTOR muscular, y reguló al alza genes de remodelación muscular. El peso corporal, otras medidas metabólicas y los marcadores circulantes se mantuvieron en gran medida sin cambios.
Who this may not transfer to:The trial enrolled only postmenopausal women with prediabetes; whether the muscle insulin-sensitivity effect transfers to men, to premenopausal women or to metabolically healthy people has not been tested.
The study · 1
Yoshino et al. 2021, Science (NMN increases muscle insulin sensitivity in prediabetic women) · Science
Muscle And Strength
Ni el NMN ni el NR mejoraron la masa muscular, la fuerza de agarre ni la velocidad de la marcha en adultos mayores de 60 años
Al sumar los ensayos, el NMN y el NR no mejoraron el tamaño muscular, la fuerza de agarre ni la velocidad al caminar en adultos mayores. Las afirmaciones sobre fuerza y función no se sostuvieron.
Una revisión sistemática y metaanálisis (Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle) de ECA en adultos con una edad media de 60.9 a 83 años encontró que el NMN no tuvo un efecto significativo sobre el índice de músculo esquelético, la fuerza de agarre, la velocidad de la marcha o la prueba de levantarse de la silla cinco veces, y la síntesis narrativa no mostró beneficio para la fuerza de extensión de rodilla, la SPPB o la masa muscular del muslo. El NR se asoció con una mayor distancia en la caminata de seis minutos solo en personas con enfermedad arterial periférica. Los autores concluyeron que la evidencia actual no respalda el NMN ni el NR para preservar la masa muscular y la función.
Who this may not transfer to:The null applies to older adults of both sexes with mean age over 60; it does not address younger or athletic people.
The study · 1
Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle (NMN and NR on muscle mass and function meta-analysis) · J Cachexia Sarcopenia Muscle
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Longevity And Mortality
Ningún ensayo humano ha mostrado que los precursores de NAD+ alarguen la salud o la vida; los sorprendentes resultados están en animales
Los sorprendentes resultados de longevidad están en animales. En personas, ningún ensayo ha mostrado que estos precursores ralenticen el envejecimiento o alarguen la vida.
Una revisión sistemática de ensayos de precursores de NAD+ (Gindri et al. 2024) catalogó resultados en diversas afecciones clínicas y no identificó criterios de valoración de longevidad o envejecimiento, y un metaanálisis muscular (Prokopidis et al. 2025) no encontró beneficio funcional en adultos mayores. La literatura animal muestra que la restauración de NAD+ mejora la salud y, para intervenciones relacionadas, la longevidad, pero esto no se ha traducido en un beneficio demostrado para la salud o la longevidad humanas.
Who this may not transfer to:No human healthspan or lifespan endpoint has been measured in either sex; the extension results are in animals only.
The studies · 2
Gindri et al. 2024, Am J Physiol Endocrinol Metab (safety and effectiveness of NAD systematic review) · Am J Physiol Endocrinol Metab
Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle (NMN and NR on muscle mass and function meta-analysis) · J Cachexia Sarcopenia Muscle
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Cardiorespiratory Fitness
El NMN de 600 a 1200 mg al día aumentó la capacidad aeróbica submáxima en 48 corredores, mientras que el VO2 máx no cambió
En corredores aficionados que siguieron entrenando, dosis más altas de NMN mejoraron su capacidad aeróbica submáxima, aunque su capacidad máxima no cambió.
Un ensayo aleatorizado doble ciego de cuatro brazos de seis semanas (Liao et al. 2021, J Int Soc Sports Nutr; n=48, 40 hombres y 8 mujeres) en corredores entrenados recreativamente encontró que los grupos de NMN de dosis media (600 mg) y alta (1200 mg) mejoraron el consumo de oxígeno, el porcentaje de VO2máx, y la potencia en el primer y segundo umbral ventilatorio más que el placebo. El VO2máx, el pulso de O2, el VO2 relativo a la carga de trabajo y la potencia máxima no cambiaron. Los autores atribuyeron el efecto a una mejor utilización de oxígeno del músculo esquelético.
Who this may not transfer to:The trial ran in young and middle-aged recreationally trained runners, only 8 of 48 women, so transfer to untrained or older people is untested.
The study · 1
Liao et al. 2021, J Int Soc Sports Nutr (NMN and aerobic capacity in amateur runners) · J Int Soc Sports Nutr
Getting NAD+ Up, in Order
Ways to Do It
Match what you do to what you want. If the goal is the healthspan the animal work points at, the levers with human evidence are free and come first. If the goal is to raise NAD+ specifically, the precursors do that, though whether the higher level changes how you feel or age is not established. The precursors and any metabolic use are worth talking through with a clinician first.
Exercise and not eating to excess most reliably support NAD+ and mitochondrial health in people. Both carry decades of human healthspan evidence the capsules lack. If slower aging is what draws you to precursors, start here, it is the intervention most likely to actually deliver.
The body makes NAD+ from vitamin B3 in ordinary food: fish, poultry, meat, mushrooms, peanuts, and fortified grains all supply niacin and nicotinamide. Outright NAD+ shortage from diet is uncommon on a mixed diet, so for most people the base of the pool is already covered without any supplement.
Nicotinamide (niacinamide) is a cheap, long-used form of vitamin B3 that also feeds NAD+. It does not raise NAD+ as much as NR or NMN, and it is not sold as anti-aging. If the aim is simply to cover B3 at low cost, it does that, and it has the longest safety record of any form here.
NR is the precursor with the most human pharmacology behind it and a clearer regulatory footing in the United States, where it is an accepted dietary ingredient. Trial doses run around 250 to 1000 mg a day. It raises NAD+ dependably; the functional benefits beyond that are not established.
NMN raises NAD+ as well, and it carries the two most interesting human leads: better insulin sensitivity in postmenopausal prediabetic women, and improved aerobic capacity in runners. Its US regulatory status is unsettled, it sits in a gray zone though it is widely sold. Doses in trials run about 250 to 900 mg a day.
The lone clean positive result came from that same prediabetic group. For a diagnosed metabolic problem, decide it with the clinician tracking your numbers. Diet, movement, and any prescribed medication are what manage it; the pooled trials did not find an average glucose benefit from a precursor.
Go Deeper
- IV therapy and NAD+: the infusion version of the same idea, and how its outcome evidence compares with a daily oral precursor.
- The biology of aging: where NAD+ decline ranks among the drivers of aging, and how to read a marker that can move while the outcome does not.
- Rapamycin: the other longevity frontier with a strong animal record and early human aging data, and the same animal-to-human gap.
- Mitochondria: the cell's power plants that NAD+ helps run, and the reason energy is the mechanism most people have in mind here.
The Chinese Medicine View
NAD+ and its precursors are products of 20th-century biochemistry, isolated and synthesized in a laboratory, so the classical Chinese pharmacopoeia has no entry for them. No historical text assigns NMN or NR a channel, a temperature, or a flavor, and reading one back in would be invention. What the tradition offers instead is a way of thinking about aging and about building the body up.
These precursors target the reserve loss that comes with age. Chinese medicine has always reasoned about that loss, chiefly through the Kidney essence, the deep constitutional reserve it ties to growth, aging, and vitality. The tradition holds this reserve is largely fixed at birth and spent across a lifetime, conserved and supported but not simply refilled from a bottle.
Tonifying, bu, is the family of methods for building up a true deficiency, and its art is judging whether the person has one and can transform what is given. Giving more than the system can use does not build reserve; it stagnates. Yang Sheng, the cultivation of life, rests on moderation, movement, and conserving reserves. In this tradition a tonic is matched to the person, never handed to everyone alike.
Cautions For This Practice
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Bien tolerado durante semanas a meses en 489 personas, con solo efectos leves; el uso más prolongado no se ha estudiado
Una revisión sistemática de ensayos aleatorizados de NAD+ y NADH en diversas afecciones clínicas (Gindri et al. 2024, Am J Physiol Endocrinol Metab; 10 estudios, 489 participantes) encontró que la suplementación se toleró bien con una baja incidencia de efectos secundarios, siendo los más comunes el dolor muscular, el dolor de cabeza, la fatiga y la alteración del sueño, y sin riesgos graves para la salud. Ensayos dedicados de NR (Martens et al. 2018) y NMN (Yi et al. 2023) reportaron de forma similar una buena tolerabilidad durante sus ventanas de estudio.Gindri et al. 2024, Am J Physiol Endocrinol Metab (safety and effectiveness of NAD systematic review)Martens et al. 2018, Nat Commun (NR well-tolerated)
The aging payoff is an animal result, so treat anti-aging use as experimental
The lifespan and healthspan gains are a mouse result. Taking NMN or NR to live longer is a self-experiment. Do not let a capsule crowd out the exercise and eating habits with real human healthspan evidence.
Short-term safety looks good, long-term is unstudied
Across the human trials, NR and NMN were well tolerated for weeks to a few months. Effects were mostly mild (nausea, headache, fatigue) with no serious adverse events reported. No trial has run past a few months, so multi-year safety is simply unstudied. Years is the timescale anyone taking them for aging has in mind.
A theoretical concern with cancer, still unresolved
NAD+ fuels the growth and repair machinery of all cells, including cancerous ones. Some laboratory work raises the question of whether pushing NAD+ up could feed an existing tumor. It has not been shown to happen in people and stays theoretical. Still, anyone with a current or recent cancer should clear NAD+ precursors with their oncologist first.
NMN sits in a regulatory gray zone
In the United States the FDA has taken the position that NMN is excluded from the dietary-supplement definition. The reason: it was authorized for study as a drug before it was marketed as a supplement. It is nonetheless widely sold, and enforcement has been inconsistent. This does not make NMN dangerous, but the usual supplement oversight is uncertain.
Kidney or liver disease, pregnancy, and medication overlap
These precursors are processed and cleared by the body like other nutrients, and the trials showing they are tolerated were mostly in reasonably healthy adults. Supplemental doses have not been studied in kidney or liver disease, pregnancy, breastfeeding, or alongside metabolic medication. In any of those cases, clear it with your clinician first.
Buy tested, and keep the dose in the studied range
Supplements are loosely regulated. An independent testing mark such as NSF or Informed Choice is the simplest proof the label matches the contents, it matters most for NMN. Keep the dose within the range the trials used; there is no established reason to exceed it, and more is not known to be better.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
What is the difference between NMN and NR?
For raising blood NAD+, they are broadly interchangeable, and neither has a demonstrated advantage over the other. They differ in two side matters: NR carries the longer record of human pharmacology, and NMN the more interesting narrow leads. Their US legal standing differs too. Pick on those terms; the core effect is the same either way.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 12 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.